We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+2.22%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$563M
AUM Growth
+$168M
Cap. Flow
+$106M
Cap. Flow %
18.87%
Top 10 Hldgs %
78.85%
Holding
47
New
15
Increased
6
Reduced
2
Closed
11

Top Buys

Rank Stock Value
1
KYNB
Kyntra Bio
KYNB
+$43M
2
FBRX icon
Forte Biosciences
FBRX
+$22.5M
3
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$16.5M
4
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$14.7M
5
EDIT icon
Editas Medicine
EDIT
+$12.9M

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$13.3M
2
ATRA icon
Atara Biotherapeutics
ATRA
+$8.94M
3
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$5.68M
4
XNCR icon
Xencor
XNCR
+$5.62M
5
KURA icon
Kura Oncology
KURA
+$5.26M

Sector Composition

Rank Sector Weight
1 Healthcare 76.97%
2 Miscellaneous 23.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXN
1
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$78.2M 13.89%
+569,500
New +$66.3M
IRWD icon
2
Ironwood Pharmaceuticals
IRWD
$682M
$70.9M 12.58%
4,481,840
+1,012,655
+29% +$14.7M
ASMB icon
3
Assembly Biosciences
ASMB
$694M
$60.8M 10.79%
245,264
– –
KYNB
4
Kyntra Bio
KYNB
$32.5M
$51.2M 9.09%
63,418
+61,738
+3,675% +$43M
LKFT
5
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$44.3M 7.86%
578,505
+27,464
+5% +$2.31M
ASND icon
6
Ascendis Pharma A/S
ASND
$16.3B
$41.2M 7.31%
1,482,600
+456,900
+45% +$12.1M
GILD icon
7
CALL
Gilead Sciences
GILD
$181B
$38M 6.75%
500,000
– –
SGMO
8
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$22.6M 4.01%
+2,568,119
New +$16.5M
KURA icon
9
Kura Oncology
KURA
$1.13B
$18.9M 3.36%
2,033,622
-578,284
-22% -$5.26M
FBRX icon
10
Forte Biosciences
FBRX
$18.1M 3.21%
+4,006
New +$22.5M
CTMX icon
11
CytomX Therapeutics
CTMX
$699M
$12.3M 2.19%
794,969
– –
EDIT icon
12
Editas Medicine
EDIT
$485M
$12M 2.14%
+717,107
New +$12.9M
CASC
13
DELISTED
Cascadian Therapeutics, Inc.
CASC
$11.1M 1.98%
3,000,000
– –
CRVS icon
14
Corvus Pharmaceuticals
CRVS
$1.19B
$9.74M 1.73%
+805,000
New +$8.59M
VRTX icon
15
CALL
Vertex Pharmaceuticals
VRTX
$137B
$9.11M 1.62%
+60,000
New +$7.22M
FATE icon
16
Fate Therapeutics
FATE
$291M
$8.22M 1.46%
2,537,026
– –
ATYR
17
aTyr Pharma
ATYR
$53M
$7.79M 1.38%
163,761
– –
TPST icon
18
Tempest Therapeutics
TPST
$17.5M
$5.48M 0.97%
1,201
– –
ACRS icon
19
Aclaris Therapeutics
ACRS
$885M
$5.03M 0.89%
185,472
-487,628
-72% -$13.3M
KIN
20
DELISTED
Kindred Biosciences, Inc.
KIN
$4.69M 0.83%
544,880
– –
TTPH
21
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$4.52M 0.8%
+31,670
New +$4.89M
EDIT icon
22
CALL
Editas Medicine
EDIT
$485M
$4.32M 0.77%
+255,000
New +$4.6M
RGLS
23
DELISTED
Regulus Therapeutics
RGLS
$3.66M 0.65%
30,910
+18,327
+146% +$3.06M
ACHN
24
DELISTED
Achillion Pharmaceuticals
ACHN
$3.41M 0.61%
+742,835
New +$2.99M
NBRV
25
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$2.77M 0.49%
1,059
– –
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2017 Portfolio in Review

As of Q2 2017, EcoR1 Capital held 47 positions worth $563M, up 42% from $396M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

EcoR1 Capital deployed $106M of net new capital in Q2 2017, opening 15 new positions and adding to 6 existing holdings. Its largest new stake was Forte Biosciences: 4,006 shares worth $18.1M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 86% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Aclaris Therapeutics, an estimated $13.3M trimmed.

  • EcoR1 Capital's largest Q2 2017 buy was Forte Biosciences: 4,006 shares worth $18.1M.
  • EcoR1 Capital added most to Kyntra Bio in Q2 2017, an estimated $43M increase.
  • EcoR1 Capital's biggest Q2 2017 reduction was Aclaris Therapeutics, cutting an estimated $13.3M.
  • EcoR1 Capital fully exited Atara Biotherapeutics in Q2 2017, selling an estimated $8.94M.
  • EcoR1 Capital's ten largest holdings make up 79% of its $563M portfolio in Q2 2017.
  • EcoR1 Capital opened 15 new positions and closed 11 in Q2 2017.
  • EcoR1 Capital's portfolio value rose 42% quarter-over-quarter to $563M.

Based on EcoR1 Capital's 13F filing for Q2 2017, filed 14 Aug 2017.